# Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)

> **NCT01215110** · PHASE2 · COMPLETED · sponsor: **Global Alliance for TB Drug Development** · enrollment: 68 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** TMC207
- **DRUG:** Rifafour e-275 mg

## Key facts

- **NCT ID:** NCT01215110
- **Lead sponsor:** Global Alliance for TB Drug Development
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-08
- **Final completion:** 2010-09
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2017-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01215110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01215110, "Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01215110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*